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Background: Changing perspectives on the natural history of celiac disease (CD), new serology and genetic tests,
and amended histological criteria for diagnosis cast doubt on past prevalence estimates for CD. We set out to
establish a more accurate prevalence estimate for CD using a novel serogenetic approach.
Methods: The human leukocyte antigen (HLA)-DQ genotype was determined in 356 patients with ‘biopsy-confirmed’
CD, and in two age-stratified, randomly selected community cohorts of 1,390 women and 1,158 men. Sera were
screened for CD-specific serology.
Results: Only five ‘biopsy-confirmed’ patients with CD did not possess the susceptibility alleles HLA-DQ2.5, DQ8, or
DQ2.2, and four of these were misdiagnoses. HLA-DQ2.5, DQ8, or DQ2.2 was present in 56% of all women and men
in the community cohorts. Transglutaminase (TG)-2 IgA and composite TG2/deamidated gliadin peptide (DGP) IgA/
IgG were abnormal in 4.6% and 5.6%, respectively, of the community women and 6.9% and 6.9%, respectively, of
the community men, but in the screen-positive group, only 71% and 75%, respectively, of women and 65% and
63%, respectively, of men possessed HLA-DQ2.5, DQ8, or DQ2.2. Medical review was possible for 41% of
seropositive women and 50% of seropositive men, and led to biopsy-confirmed CD in 10 women (0.7%) and 6 men
(0.5%), but based on relative risk for HLA-DQ2.5, DQ8, or DQ2.2 in all TG2 IgA or TG2/DGP IgA/IgG screen-positive
subjects, CD affected 1.3% or 1.9%, respectively, of females and 1.3% or 1.2%, respectively, of men. Serogenetic data
from these community cohorts indicated that testing screen positives for HLA-DQ, or carrying out HLA-DQ and
further serology, could have reduced unnecessary gastroscopies due to false-positive serology by at least 40% and
by over 70%, respectively.
Conclusions: Screening with TG2 IgA serology and requiring biopsy confirmation caused the community
prevalence of CD to be substantially underestimated. Testing for HLA-DQ genes and confirmatory serology could
reduce the numbers of unnecessary gastroscopies.
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It is not uncommon for patients suspected of having ce-
liac disease (CD) to be reluctant to undergo definitive
testing by small bowel biopsy. By contrast, an online
community survey of randomly selected Australians in-
dicated that 28% of adults monitor their dietary gluten
intake, with 4% avoiding it altogether, 5% strictly con-
trolling intake, and a further 18% loosely controlling
consumption (Coeliac Australia, personal communica-
tion). Despite the current popularity of gluten-free food,
it is unclear what proportion of the community with CD
is diagnosed or remains unrecognized [1,2].
Over the past 20 years or more, widely implemented
expert guidelines have recommended that diagnosis of
CD should be based on small bowel histology showing
villous atrophy and confirmed by symptoms, laboratory
abnormalities, and/or intestinal histology showing im-
provement with exclusion of dietary gluten [3]. However,
several developments have challenged this definition. Re-
cently the European Society for Pediatric Gastroenter-
ology, Hepatology, and Nutrition (ESPGHAN) Working
Group on Coeliac Disease Diagnosis proposed that CD
should be redefined as ‘an immune-mediated systemic
disorder elicited by gluten and related prolamines in
genetically susceptible individuals, characterized by the
presence of a variable combination of gluten-dependent
clinical manifestations, CD-specific antibodies, human
leukocyte antigen (HLA)-DQ2 and HLA-DQ8 haplo-
types, and enteropathy’ [4]. The ESPGHAN Working
Group also concluded CD is frequently difficult to
recognize ‘because of the variation in presentation and
intensity of symptoms and signs, and many cases may
actually occur without symptoms’ [4]. Consequently, a
new approach to the diagnosis of CD has recently been
published, in which for the first time, HLA-DQ geno-
typing was included as the initial step in testing for CD
in patients who are considered at risk of CD, but do
not have the typical symptoms. In many countries with
sophisticated healthcare such as the USA and most of
Europe, by far the majority of patients with CD in the
community remain undiagnosed and do not present to
their physicians with the so-called ‘typical’ digestive
symptoms. However, patients presenting in primary
care and in many sub-specialty clinics frequently have
symptoms and co-morbidities that raise the possibility
of CD, or might have adopted a gluten-free diet without
prior assessment for CD [5]. Even if physicians were
more aware of the diverse clinical presentations of CD
and the availability of new serological and genetic tests,
it is not yet clear how to efficiently and cost-effectively
assess the possibility of CD in patients without typical
gastrointestinal symptoms.
Almost all credible community prevalence studies for
CD have relied on sera being initially screened by ‘CD-specific serology’, followed by additional supportive ser-
ology or ‘definitive’ intestinal histology showing villous
atrophy [2]. However, the frequencies of false-positive
and false-negative IgA endomysial immunofluorescence
(EMA) and tissue transglutaminase (TG)-2 serology as-
says can vary widely. In part, this uncertainty arises be-
cause abnormal intestinal histology remains the gold
standard for diagnosis. In community prevalence studies,
there is the practical problem that many subjects are un-
able or refuse to have gastroscopies to allow intestinal
histology to be ascertained. A further issue is what con-
stitutes abnormal histology compatible with CD, particu-
larly if only mild inflammation showing increased
density of intra-epithelial lymphocytes (IELs) is found
without evidence of villous atrophy [1,6-10].
The first CD prevalence studies from Australia high-
light these challenges [11,12]. Based on a single set of
sera collected 5 years earlier, 10 of 3,011 adults were
found to be positive for EMA, and all 7 who underwent
gastroscopy were confirmed by intestinal histology as
having CD, thus when 2 cases already diagnosed based
on biopsy were combined with those found by screening,
the estimated prevalence of CD was 0.4%. In a follow-up
study 5 years later, using the same serum set, TG2 IgA
or IgG serology was found to be raised in 47 sera, and
CD was confirmed after intestinal histology in 14 of 31
seropositive subjects available for follow-up [11]. Thus,
the investigators offered a revised prevalence estimate of
at least 0.56% based on histology-confirmed cases, but
proposed that the rate of affected subjects could be as
high as 0.96% if other seropositive subjects who carried
HLA-DQ2 or DQ8 were also included.
An outstanding feature of CD is that almost all
affected individuals possess immune recognition genes
encoding either HLA-DQ2.5, DQ8, or DQ2.2, which fa-
cilitate CD4 T-cell recognition of specific gluten-derived
peptides [13-17]. HLA typing for DQ2.5, DQ8, and/or
DQ2.2 is an exceptionally powerful negative predictor,
but is of little value as a positive predictor of CD in indi-
vidual patients, because these susceptibility genes are
found in 30 to 40% of the general community. Large-scale,
high-throughput HLA-DQ genotyping is now inexpensive
in the research setting, but remains surprisingly expensive
in some healthcare systems when used in clinical practice.
In the current study, we tested the positive predictive
power of HLA-DQ genotyping and serology to estimate
the prevalence of CD at a population level. This novel ap-
proach has the potential to overcome the limitations im-
posed by the requirement for intestinal histology to assess
population prevalence accurately. Our findings also led us
to develop a series of diagnostic algorithms to compare
costs and resource utilization, and these could be used to
inform clinical decision-making when evaluating the pos-
sibility of CD in patients not considered at high risk.
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Study populations
The community cohorts used in this study have been
described previously [18,19]. Briefly, subjects were
recruited to both female and the male age-stratified,
randomly selected cohorts, based on the electoral rolls
in the Barwon Statistical Division, a geographically
well-defined, large, stable population of 259,013 people
(2006 Australian Bureau of Statistics Catalogue number
2001.0) whose educational and socioeconomic charac-
teristics and age structure differ by less than 5% from
the national Australian profiles [19]. Participation rates
were 77% for the female cohort and 65% for the male
cohort. The female cohort was recruited between 1994
and 1997 (n = 1494; median age 54 years, range 20 to
94 years), and the male cohort was recruited between
2001 and 2006 (n = 1540; median age 56 years, range
20 to 97 years). Blood was taken from all participants at
enrolment after an overnight fast. Sera that were stored
frozen at −80°C for 13 to 16 years (females) or 4 to 9
years (males) were available for 1,390 women and 1,158
men. DNA extracted from whole blood and then stored
at −80°C was also available for 1,177 of the women and
1,056 of the men who had provided sera. Frozen sera
collected 10 years later were also available from 597 of the
1,390 subjects in the female cohort. Subjects in the female
cohort were invited to return every 2 years, and those in
the male cohort to return every 5 years. At enrolment and
at each review, participants completed questionnaires
about their demographics, general health, medication ex-
posure, and disease histories. Medical history was de-
rived from the self-reported history of diseases, and
where possible validated by reference to the partici-
pants’ medical records. In 2010, volunteers whose de-
identified data indicated abnormal composite TG2/
deamidated gliadin peptide (DGP) IgG and IgA ser-
ology that was then confirmed by raised levels of TG2
IgA, DGP IgG (DGP-G), or DGP IgA (DGP-A) were
contacted by letter and informed that their blood tests
suggested CD, and that although this did not diagnose
CD, they ought to see their doctor as soon as possible
to discuss appropriate management.
In a separate study, volunteers aged between 18 and
70 years old with ‘biopsy-confirmed’ CD based on the
1990 ESPGHAN diagnostic criteria [3] were recruited at
The Royal Melbourne Hospital following advertisements
in the Victorian State Coeliac Society newsletter. HLA-
DQ genotypes were established for these subjects, and
these have been partially reported elsewhere [17].
Ethics
Approval by the appropriate ethics committees was
obtained by each of the participating centers. The
Barwon Health Human Research and Ethics Committeegranted approval for the original prospective commu-
nity cohorts (92/01 and 00/56). An amendment in 2009
allowed testing for CD (92/01-s5 and 00/56-s5), and
The Melbourne Health Human Research Ethics Com-
mittee approved recruitment of volunteers with biopsy-
confirmed CD for the study ‘Gluten Immunity in
Coeliac Disease’ (2003.009). Written informed consent
was obtained from each volunteer participating in the
study.
Serology
A single clinical diagnostic immunology scientist (RT)
performed all serological assays in a commercial path-
ology laboratory (Healthscope Pathology, Clayton,
Victoria, Australia). Sera from 1,390 women (95% of the
female cohort) and 1,158 men (98% of the male cohort)
were thawed once, divided into smaller aliquots, and
stored at −80°C before being transferred to the clinical
laboratory. The thawed sera were tested in batches for
anti-native human TG2 IgA (h-tTG IgA; QUANTA
Lite®; product number 708760), anti-gliadin IgG (AGG;
QUANTA Lite® Gliadin IgG; number 708650), anti-
gliadin IgA (AGA; QUANTA Lite® Gliadin IgA; number
708655) (all INOVA Diagnostics Inc., San Diego, CA,
USA), and in a composite antigen ELISA that measures
IgA and IgG specific for native human red cell-derived
TG2 and synthetic, deamidated gliadin-derived pep-
tides (composite TG2/DGP IgA/IgG; QUANTA Lite®
h-tTG/DGP Screen; number 704575; INOVA Diagnos-
tics Inc.). If the result of the initial TG2 IgA ELISA
was at or above the manufacturer’s cut-off value of 20
units, then a sample of the same aliquot of serum was
also tested for EMA (monkey esophagus IFA Kit; bind-
ing site FK208.2/INOVA number I704150; INOVA
Diagnostics Inc.). When EMA was negative and TG2
IgA abnormal, the same serum was tested using an-
other commercial TG2 IgA ELISA kit (1910–9601 A;
Euroimmun AG, Lubeck, Germany). If the result of the
composite TG2/DGP IgA/IgG screen was at or above
the manufacturer’s upper limit of normal (ULM), that
is 20 U,) the same sample of serum was tested for TG2
IgA (QUANTA Lite® h-tTG IgA; number 708760),
DGP-G (QUANTA Lite® Gliadin IgG II; number
704520) and DGP-A (QUANTA Lite® Gliadin IgA II;
number 704525) (all INOVA Diagnostics Inc.)
HLA-DQ genotyping
In the community cohort, DNA was extracted from the
blood collected at enrolment. Five single-nucleotide poly-
morphisms (SNPs) (rs2187668, rs2395182, rs4713586,
rs7454108, and rs7775228) in linkage disequilibrium with
the CD-associated HLA risk factors DQ2.5, DQ8, and
DQ2.2, which indicate direct risk, and with DQA1*0505/
DQB1*0301 (DQ7), which contributes to the risk of
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DQB1*0202 (DQ2.2) were used to determine HLA-DQ
haplotypes, as previously described [20,21]. Genotyping
was performed by the Human Genetics Group (t the
University of Queensland Diamantina Institute) using
Taqman SNP genotyping methods (Applied Biosystems,
Foster City, CA, USA) following the manufacturer’s proto-
cols. Full SNP-based HLA-DQ genotyping was possible
for 1,065 (90%) of the 1,177 DNA samples provided from
the female cohort and 921 (87%) of the DNA samples
from the male cohort; hence, complete HLA-DQ geno-
type and serology datasets were available for 73% of the
total female cohort and 78% of the total male cohort. For
subjects from the cohort of patients with biopsy-
confirmed CD and for subjects in the community female
and male cohorts with higher readings in the composite
TG2/DGP IgA/IgG screen, which were subsequently con-
firmed by increased TG2 IgA, DGP-G or DGP-A levels,
the HLA-DQ genotypes were also determined in a clin-
ical immunogenetics laboratory using the PCR to
sequence-specific oligonucleotide (SSO) hybridization
method (Victorian Transplantation and Immunogenet-
ics Service, Parkville, VIC, Australia) [22-24]. HLA-
DQ2.5, DQ8, and DQ2.2 genotypes determined by both
methods for 73 subjects were in agreement, except in 1
case. which was determined to be HLA-DQ2.5+DQ8-
DQ2.2- by SSO and HLA-DQ2.5-DQ8-2.2+ by SNP
genotyping.
Statistical analysis
The GraphPad Prism software package (GraphPad Soft-
ware, Inc. La Jolla, CA, USA) was used for statistical cal-
culations. Serological status and HLA-DQ genotype were
compared by Fisher’s exact test. A probability of less than
5% by two-tailed analysis was taken to be significant.
For the 1,065 subjects from the female cohort, and 921
subjects from the male cohort with paired HLA-DQ geno-
type and serology data, the estimated number with CD (n)
was calculated using contingency tables as the excess of
subjects found to be positive for one or an indicated series
of serological tests and also gene-positive for HLA-DQ2.5,
DQ8, or DQ2.2 (aO) above those expected (aE), minus the
difference between the observed (cO) and expected (cE)
number of subjects who were seropositive and gene-
negative for HLA-DQ2.5, DQ8, and DQ2.2:
n ¼ aO−aEð Þ− cO−cEð Þ ð1Þ
here the expected number of seropositive and gene-
positive subjects is:
aE ¼ aO þ cOð Þ  aO þ bOð Þ
 aO þ bO þ cO þ dOð Þ ð2Þ
where bO is the observed number of seronegative andgene-positive subjects, and dO is the observed number of
seronegative and of gene-negative subjects. Similarly, the
expected number of seropositive and of gene-negative
subjects is given by:
cE ¼ aO þ cOð Þ  cO þ dOð Þ
 aO þ bO þ cO þ dOð Þ ð3Þ
The upper (nUL) and lower (nLL) 95% confidence inter-
vals (CIs) for the estimated numbers of subjects with CD
(n) were derived using equation 1, and the upper (RRUL)
and lower (RRLL) 95% confidence intervals of the relative
risk (RR) for being gene-positive in the seropositive sub-
jects were calculated by GraphPad Prism, thus:
RR ¼ aO  aO þ cOð Þð Þ  bO  bO þ dOð Þð Þ ð4Þ
and therefore, the upper 95% CI for the number of sub-
jects seropositive and gene-positive (aUL) is given by:
aUL ¼ RRUL  aO þ cOð Þ  bOð Þ  bO þ dOð Þ ð5Þ
Similarly, the lower 95% CI (aLL) for the number of
subjects seropositive and gene-positive is given by:
aLL ¼ RRLL  aO þ cOð Þ  bOð Þ  bO þ dOð Þ ð6Þ
The upper 95% CI for the number of subjects sero-
positive and gene-negative (cUL) is then:
cUL ¼ aO þ cOð Þ−aUL ð7Þ
and similarly, the lower 95% CI for the number of sub-
jects seropositive and gene-negative (cLL) is then:
cLL ¼ aO þ cOð Þ−aLL ð8Þ
Thus, the upper 95% CI (nUL) for the number of sub-
jects with CD is given by:
nUL ¼ aUL−aEð Þ þ cE−cULð Þ ð9Þ
and the lower 95% CI (nLL) for the number of cases with
CD is then:
nLL ¼ aLL−aEð Þ þ cE−cLLð Þ ð10Þ
Costing of diagnostic algorithms
Australia has a publicly funded health system that pro-
vides primary healthcare treatment for all Australian cit-
izens and permanent residents, and is operated by the
government authority Medicare Australia. To estimate
the cost of investigations incurred for a hypothetical co-
hort of 1,000 adult men or women in the community be-
ing tested for CD, the full Australian Medicare Benefits
Schedule fees were applied (http://www9.health.gov.au/
mbs/search.cfm). The cost code 71163 (A$1 = US$0.91;
A$24.90) was applied for initial TG2 IgA estimation or
composite TG2/DGP IgA/IgG screen; 71164 (A$40.15)
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or TG2 IgA, DGP-G, and DGP-G; 71151 (A$119.65)
for HLA-DQ genotyping; and an aggregated estimate of
A$850 for diagnostic gastroscopy performed in a com-
munity endoscopy center by a specialist gastroenterolo-
gist, with sedation provided by a medical practitioner
sedationist, and standard histology of five biopsies col-
lected from the proximal small intestine. The costs of
follow-up appointments with the treating doctor, and
personal costs borne by the patient associated with at-
tendance for blood collection and gastroscopy were not
included. For the purpose of modeling the effectiveness
of the diagnostic algorithms, we assumed that small
bowel histology correctly identified all patients with CD
predicted by serogenetic prevalence estimates. How-
ever, it should be noted that small bowel biopsies col-
lected from approximately 10% of patients are not
suitable for definitive diagnosis, and inter-observer
variability between histopathologists can be substantial
[25,26]. Per capita claims to Medicare Australia for one






F + M 356 351 1.78 (1.71 t
Biopsy-confirmed CD; four of five HLA-DQ2.5-DQ8-DQ2.2- re-investigated
F + M 352 351 1.80 (1.73 t
Community random sample of age-stratified cohorts of adults
F 1,065 596 1
M 921 513 1
Community sample: initially positive for TG2 IgA
F 48 34 (27) 1.28 (1.06 t
M 68 44 (38) 1.18 (0.98 t
Community sample: initially positive for TG2 IgA, and confirmed positive for
F 13 13 (7) 1.80 (1.71 t
M 13 13 (7) 1.82 (1.71 t
Community sample: initially positive for composite TG2/DGP IgA/IgG
F 55 41 (31) 1.36 (1.15 t
M 73 46 (41) 1.14 (0.95 t
Community sample: initially positive for composite TG2/DGP IgA/IgG, and co
F 37 30 (21) 1.47 (1.23 t
M 44 29 (25) 1.19 (0.96 t
Community sample: – initially positive for TG2/DGP IgA/IgG, and confirmed p
F 10 10 (6) 1.80 (1.71 t
M 11 11 (6) 1.82 (1.72 t
Abbreviations: CD, celiac disease; DGP, Deamidated gliadin-derived peptide; EMA, e
Ig, immunoglobulin; M, male; NA, not applicable; NS, not significant; RR, relative risk




HLA-DQ status and biopsy-confirmed CD
We first determined the prevalence of HLA-DQ2.5,
DQ8, or DQ2.2 in local members of the celiac support
group who responded to an invitation for volunteers
with ‘biopsy-proven’ CD. Of 356 patients with a diagno-
sis of CD confirmed by small bowel histology, HLA-
DQ2.5 was present in 325 patients (91.3%), HLA-DQ8
but not HLA-DQ2.5 was found in 19 (5.3%), and DQ2.2
but not HLA-DQ2.5 or HLA-DQ8 was present in 7
(2.0%) (Table 1); only 5 patients (1.4%) lacked HLA-DQ2
.5, HLA-DQ8 and HLA-DQ2.2. Clinical review led to
CD being excluded in four of these ‘gene-negative’ cases
because the small bowel histology remained normal after
prolonged gluten challenge, and in two cases because
the intestinal histology and further investigations led to











o 1.55)b 14 13.4 (2.4 to 26.8)
o 1.42)NS 12 13.2 (−2.9 to 32.8)
EMA
o 1.90)c 11 10.8 (9.5 to 12.1)
o 1.93)c 12 12.5 (10.9 to 14.2)
o 1.60)d 20 19.2 (7.5 to 32.9)
o 1.38) NS 11 11.6 (−5.4 to 32.0)
nfirmed positive for TG2 IgA, DGP-G-+, or DGP-A
o 1.74)e 19 17.5 (8.9 to 27.6)
o 1.49) NS 9 9.8 (−2.7 to 25.3)
ositive for TG2 IgA, DGP-G, and DGP-A
o 1.90)d 9 8.3 (7.3 to 9.3)
o 1.93)e 10 10.6 (9.3 to 12.1)
ndomysial immunofluorescence IgA; F, female; HLA, human leukocyte antigen;
; TG2, transglutaminase-2.
0.005, eP<0.002, (Fisher’s exact test, two-tailed).
Figure 1 Human leukocyte antigen (HLA-DQ genetic status and
celiac disease (CD)-specific serology. (A) HLA-DQ status of female
(F) and male (M) community cohorts, and those who tested positive
for anti-gliadin IgG (AGG) , anti-gliadin IgA (AGA), IgA specific for
native human transglutaminase (TG)2, and composite TG2/DGP IgA/
IgG (Comp.). Total numbers of subjects are in brackets. (B) HLA-DQ
genotypes of women and men in the combined community
cohorts classified by measured level of TG2 IgA and whether
endomysial antibody (EMA) was also positive; or composite TG2/
DGP IgA/IgG (Comp.) and whether all or at least one confirmatory
serology (TG2 IgA, DGP IgA, or DGP IgG) was abnormal. Numbers of
subjects are in brackets. DGP, Deamidated gliadin-derived peptide.
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clinical re-evaluation. Hence, at least 99.7% of local pa-
tients with histology-confirmed CD possessed HLA-
DQ2.5, HLA-DQ8, or HLA-DQ2.2.
Community prevalence of celiac disease HLA-DQ
susceptibility genotypes
In the female and male cohorts recruited from the com-
munity, 55.9% and 55.7% of genotyped subjects, respect-
ively, were genetically susceptible to CD because they
were positive for HLA-DQ2.5, DQ8, or DQ2.2. The pro-
portions of the genotyped women and men positive for
HLA-DQ2.5 were virtually identical: 24.3% versus 24.7%,
respectively. Subjects negative for HLA-DQ2.5 but posi-
tive for HLA-DQ8 accounted for 15.7% of women and
16.1% of men; and subjects who were negative for both
HLA-DQ2.5 and HLA-DQ8 but positive for HLA-DQ2.2
represented 16.0% of women and 15.0% of men. Accord-
ingly, the RR for HLA-DQ2.5, DQ8, or DQ2.2 in patients
with CD compared with community subjects was 1.80
(95% CI 1.71 to 1.90) for women and 1.82 (95% CI 1.71
193) for men (Table 1).
TG2 IgA serology and genetic evidence of celiac disease
in the community
Abnormal TG2 IgA serology was found in 64 of 1,390
women (4.6%) and 80 of 1,158 men (6.9%). Although
genetic susceptibility to CD was more common in sero-
positive women than in the community cohort (P<0.04)
and showed a positive though non-significant trend in
men, 29% of the women and 35% of the men who were
seropositive for TG2 IgA were not genetically suscep-
tible to CD (Figure 1A, Table 1). Higher levels of TG2
IgA were more strongly associated with HLA-DQ2.5,
DQ8, and DQ2.2, and all 16 subjects with TG2 IgA
levels above 85 U (4.5 × ULN) possessed HLA-DQ2.5 or
HLA-DQ8 (Figure 1B). By contrast, genetic susceptibility
to CD was the same in subjects with TG2 IgA levels of
20 to 40 U (53%) as it was in seronegative subjects
(54%). Based on the absence of genetic susceptibility to
CD in approximately one-third of subjects with sera
showing increased levels TG2 IgA, it was clear that
false-positive TG2 IgA findings are common in adults in
the community. Hence, TG2 IgA serology alone would
substantially overestimate the community prevalence of
CD, and in clinical practice would be expected to result
in many unnecessary gastroscopies to exclude CD.
These observations prompted us to formalize a simple
method using contingency table analysis and RR to esti-
mate the prevalence of CD using CD-associated serology
and genetic susceptibility, assuming that all individuals
with CD possessed HLA DQ2.5, DQ8, or DQ2.2 (see
Statistical analysis). Subsequent analysis focused on
1,065 subjects from the female cohort and 921 from themale cohort with both serology and HLA-DQ status
determinations. Based on this analysis, the observed en-
richment for genetic susceptibility to CD in TG2 IgA-
seropositive women and men could be accounted for if
14 of 48 seropositive women and 12 of 68 seropositive
men had CD. These figures implied that only 14 of 34
women and 12 of 44 men with raised levels of TG2 IgA
who possessed HLA-DQ2.5, DQ8, or DQ2.2 were actu-
ally affected by CD, and that the prevalence of CD was
approximately 1.3% in both the female and male cohorts
(Table 1; Figure 2).
To improve the precision of these prevalence esti-
mates, ‘confirmatory’ EMA tests were performed and
found to be positive in 13 women and 13 men with
raised TG2 IgA levels. All 26 TG2 IgA+ EMA+ subjects
possessed HLA DQ2.5 (P<0.0001). Hence, prevalence
Figure 2 Community prevalence estimates for celiac disease
(CD). Estimated prevalence of CD with 95% confidence intervals per
1,000 adult females (F) or male (M) subjects, based upon enrichment of
human leukocyte antigen (HLA)-DQ2.5, DQ8, and DQ2.2 in subjects
who were seropositive for transglutaminase (TG)2 IgA (TG2+), TG2 IgA
+ and then endomysial antibody (EMA)+, composite TG2/DGP IgA/IgG
(Comp+), Comp.+ and then TG2 IgA+, deamidated gliadin-derived
peptide (DGP)-G+ or DGP-A+ (Comp + One+), and for Comp+ and
then TG2 IgA+, DGP-G+ and DGP-A+ (Comp + All+).
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both TG2 IgA and EMA were 1.1% (95% CI 1.0 to 1.2%)
in women and 1.3% (95% CI 1.1 to 1.4%) in men (Table 1;
Figure 1B; Figure 2).
Expanded serological screening for celiac disease
It has been hypothesized that there are greater numbers
of individuals in the community with genetically deter-
mined gluten-mediated disease than just those with
raised levels of TG2 IgA or EMA [1,27], and some pa-
tients with biopsy-confirmed CD who are seronegative
for TG2 IgA do have raised DGP IgA or IgG levels [28].
IgA and IgG anti-gliadin antibodies (AGA and AGG,
respectively) have also been proposed as markers of
gluten-responsive irritable bowel syndrome in patients
genetically susceptible to CD. When tested in enrolment
sera, both AGG and AGA were commonly raised in
both the female (17% and 9%, respectively) and male
(21% and 12%, respectively) cohorts, but genetic suscep-
tibility to CD was not significantly increased in AGA or
AGG seropositive women (55% and 49%, respectively) or
men (62% and 52%) (Figure 1A).The composite TG2/DGP IgG/IgA screen was abnor-
mal in 78 of 1,390 women (5.6%) and 92 of 1,158 men
(6.9%). Women with positive composite TG2/DGP IgG/
IgA screen were more commonly positive for HLA-DQ2.5,
DQ8, or DQ2.2 (75%, P<0.005) (Table 1, Figure 1). In
men, over-representation of HLA-DQ2.5, DQ8, or
DQ2.2 was not as pronounced and did not reach statis-
tical significance (46/73; 63%). As observed with the
TG2 IgA serology, higher readings in the composite
TG2/DGP IgG/IgA screen were more strongly associ-
ated with genetic susceptibility to CD; all 23 subjects
with levels above 85 U (4.5 × ULM) possessed HLA-
DQ2.5 or HLA-DQ8 (Figure 1B). Based upon enrich-
ment for HLA-DQ2.5, DQ8, or DQ2.2 in subjects with
raised levels of composite TG2/DGP IgG/IgA, the
prevalence of CD was 1.9% in women and 1.2% in men
(Table 1; Figure 2). When subjects found to be sero-
positive by the composite TG2/DGP IgG/IgA screen
were tested for TG2 IgA, DGP-G, and DGP-A separ-
ately, 65% (51/78) of women and 61% (56/92) of men
had raised levels in at least one test. Prevalence esti-
mates based on genetic enrichment and ‘confirmed’ ab-
normal TG2/DGP IgG/IgA screen were 1.8% in women
and 1.0% in men (Table 1; Figure 2). All 10 women
(0.9%) and 11 men (1.2%) with raised levels of each of the
three serology tests (TG2 IgA, DGP-G, and DGP-A) were
HLA-DQ2.5+ (P<0.0001) and also EMA+.
Prospective review in seropositive cases
There was just one case of biopsy-confirmed CD at en-
rolment, a 57-year old male who was HLA-DQ2.5+ but
negative in the TG2 IgA and composite TG2/DGP IgA/
IgG screens, consistent with a diagnosis of CD but
strictly following a gluten-free diet. Follow-up of the 51
women and 56 men having serum collected at enrol-
ment who had ‘confirmed’ abnormalities after testing
positive in the composite TG2/DGP IgG/IgA screen
identified 10 women (0.7%) and 6 men (0.5%) with intes-
tinal histology showing villous atrophy, crypt hyperpla-
sia, and IELs, confirming active CD (Table 2; see
Additional file 1: Tables S1A and S1B). Four of these
women and two of these men had been diagnosed with
CD between 2004 and 2009 on the basis of typical small
bowel histology following investigation for diarrhea (n = 2),
fatigue (n = 1), iron deficiency (n = 1), or osteoporosis
(n = 1), or after diagnosis of a family member. The
other biopsy-confirmed cases resulted from gastrosco-
pies prompted by the current study in 2010. Two
biopsy-confirmed cases were in women whose enrol-
ment sera were negative for TG2 IgA, but positive for
DGP-G and DGP-A. None of the cases identified with
CD were deficient in IgA. Repeat serology after medical
review supported CD in two further women (0.1%) and
four additional men (0.3%), but these subjects were not
Table 2 Follow-up and final disposition of subjectsa
Women, n Men, n
Total subjects 1,390 1,158
CD diagnosed by histology before enrolment 0 1
Abnormal composite TG2/DGP IgA/IgG, and TG2 IgA, or DGP IgA or IgG 51 56
Findings diagnostic/supportive of untreated CD
Histological diagnosis: Intestinal villous atrophy, crypt hyperplasia, and IELs
Prompted by current study, 2010 6 4
During standard medical care between 2004 and 2009 4 2
Serological diagnosis: confirmation of multiple CD serological abnormalities
No supporting histological evidence obtained 2 3
Treating doctor excluded CD because patient was asymptomatic 0 2
Findings equivocal for CD
Intestinal IELs +/− mild focal villous atrophy, or villous atrophy and crypt hyperplasia without IELs 0 3
Findings excluded/were not supportive of CD
Normal intestinal histology without serological testing 2 5
Serological exclusion: CD serological abnormalities not replicated 7 8
Genotyping exclusion: testing for HLA DQ2.5/8/2.2 negative 0 1
Follow-up not possible or not undertaken
Treating doctor did not investigate further as subject asymptomatic and/or performed blood tests unrelated to CD 1 5
Subject deceased and CD not diagnosed pre-mortem 8 5
Subject declined follow-up medical review 16 11
Subject could not be contacted; lost to follow-up 5 7
CD cases estimated by serogenetic modeling, range 12 to 26 12 to 16
Lower 95% CI for CD cases based on TG2+ EMA+ 11 12
Abbreviations: CD, celiac disease; DGP, Deamidated gliadin-derived peptide; EMA, endomysial antibody; HLA, human leukocyte antigen; IEL, Intra-epithelial
lymphocyte; Ig, immunoglobulin; TG, transglutaminase.
aData are n, unless otherwise stated.
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rejected in two of these cases because the clinician
judged that no symptoms suggestive of CD were
present. Hence, 12 women (0.9%) and 11 men (0.9%)
with abnormal serology at enrolment had the diagnosis
of CD confirmed by histology or had repeat serology
consistent with CD. In addition, three cases had
equivocal changes on intestinal histology. In 9 women
and 14 men, CD was excluded by serology, HLA-DQ
genetic testing, or histology findings. Medical review
was not possible for 29 women and 23 men, and in 6
subjects, medical follow-up led to exclusion of CD
without further relevant investigations.
Sera collected from 597 women at the 10-year review
showed that 24 (4.0%) had persistent increases in the
composite TG2/DGP IgA/IgG and/or TG2 IgA screen; 22
of these subjects had known genotype, and of these, 21
(95%) were genetically susceptible to CD (see Additional
file 2: Table S2). At the 10-year review, serological abnor-
malities persisted in all genetically susceptible subjects
whose enrolment sera had showed a composite TG2/DGP
IgA/IgG result of 59 U or higher (n = 13) or TG2 IgA of58 U or higher (n = 11). Less pronounced increases in the
composite TG2/DGP IgA/IgG and TG2 IgA screens at en-
rolment were less often reproduced at the 10-year review.
There were three cases showing abnormalities in both
composite TG2/DGP IgA/IgG and TG2 IgA screens at
10-year follow-up that were not present at enrolment, in
two cases EMA was reported as negative and in one it was
equivocal (see Additional file 2: Table S2). Both of the ge-
notyped cases showing new serological abnormalities at
10-year follow-up were genetically susceptible to CD.
Intestinal histology was not available for these three
patients.
Diagnostic pathways
Prompted by the observed high rate of false-positive ser-
ology tests, we designed a series of diagnostic algorithms
using either TG2 IgA or composite TG2/DGP IgA/IgG
screens or HLA-DQ genotyping as the initial screen,
with or without subsequent confirmatory serology and/
or HLA-DQ genotyping prior to gastroscopy and defini-
tive small bowel histology (Table 3). The overall cost and
resource utilization of models were compared using the
Table 3 Models for initial and confirmatory testing of CD
Model Initial test Additional tests if initial test positive Definitive test
A TG2 IgA None Biopsy
B TG2 IgA HLA-DQ Biopsy if HLA-DQ2.5/2.2/8+
C TG2 IgA EMA and HLA-DQ Biopsy if HLA-DQ2.5/2.2/8+
D TG2 IgA If TG2 IgA > 10 × ULN, then EMA and HLA-DQ;
otherwise none
None if TG2 IgA > 10 × ULN, EMA abnormal and HLA-DQ2.5/2.2/8
+; otherwise biopsy









HLA-DQ, TG2 IgA, DGP-G and DGP-A Biopsy if HLA-DQ2.5/2.2/8+ and either TG2 IgA or DGP-G or
DGP-A abnormal
Abbreviations: DGP, Deamidated gliadin-derived peptide; EMA, endomysial antibody; HLA, human leukocyte antigen; TG, transglutaminase; ULN, upper limit
of normal.
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male and male cohorts. We assumed that the total num-
bers of affected cases were those predicted by genetic
enrichment in TG2 IgA or composite TG2/DGP IgA/
IgG screen-positive subjects (13/1,000 women and 13/
1,000 men, and 19/1,000 women and 12/1,000 men, re-
spectively) (Table 4). Because many cases now tested for
CD in Australia occur in the setting of primary care,
where the pre-test probability of CD is unlikely to be
substantially different from background community
prevalence, this analysis may be relevant to community
clinical practice.
Model A (initial testing for TG2 IgA followed by small
bowel biopsy) is widely recommended in clinical guide-
lines, but according to the Medicare Australia item
costs, is more expensive and results in more (unneces-
sary) gastroscopies than the model (model B) including
HLA-DQ genotyping to exclude ‘gene-negative’ TG2
IgA false-positive patients prior to biopsy. Including
both confirmatory EMA and HLA-DQ genotyping for
TG2 IgA-seropositive patients, but still performing gas-
troscopies in all of this patient group (model C) mod-
estly increases cost and has the advantage that cases
with a pre-biopsy likelihood of CD greater than 90% can
be identified to minimize the risk of biopsy false-
negatives. Model D is based on that proposed by the re-
vised ESPGHAN 2012 criteria for symptomatic children,
avoiding the requirement for biopsy in patients with TG
IgA levels greater than 10 × ULN who have confirma-
tory EMA and HLA-DQ genotyping. Only 0.2% of men
and 0.3% of women in the community would be
expected to have levels of TG2 IgA above 10 × ULN,
and model D was little different from model A in its cost
and clinical impact. Model E is based on that proposed
by the revised ESPGHAN 2012 criteria for asymptomatic
children at increased risk; the initial test is HLA-DQ
genotyping followed by biopsy if TG2 IgA is greater than3 × ULN, or if TG2 IgA is raised but is less than 3 × ULN
then confirmatory EMA is performed, and if positive,
then biopsy is undertaken. The cost associated with
model E is about double that of the next most expen-
sive model, but requires the least number of gastrosco-
pies. Model E is the same as model A except that the
composite TG2/DGP IgA/IgG screen is substituted for
TG2 IgA; it is cheaper than model A per case diagnosed
as it detects additional affected female patients who
might be TG2 IgA-seronegative. Including ‘confirmatory’
HLA-DQ genotyping also reduces the cost of initial
testing with the composite TG2/DGP IgA/IgG screen
(model G), as it did for TG2 IgA screening in model B.
Finally, in model H, biopsies are performed only in
patient with positive results on composite TG2/DGP
IgA/IgG screen who are confirmed to be genetically
susceptible to CD and who also show abnormalities in
confirmatory TG2 IgA, DGP-G or DGP-A tests. Model H
reduced the cost per case diagnosed by 38% in women
and 25% in men, and reduced the number of gastroscopies
by 38% in women and 65% in men.
Discussion
The concept of a ‘celiac iceberg’ has been important in
drawing attention to a large, unrecognized group of pa-
tients with CD who do report symptoms considered
‘typical’ of CD [29]. Investigators have proposed expan-
sion of the ‘iceberg’ to encompass patients who are gen-
etically susceptible to CD, but show only raised IEL
counts or an isolated abnormal CD-specific serology and
normal intestinal histology [30-32]. Consequently, there
is considerable uncertainty regarding the true extent of
gluten-mediated disease in the community. The recent re-
vision of diagnostic criteria proposed by the ESPGHAN
Working Group seeks to address these developments, and
increase the contribution of serology and HLA-DQ gen-
etic tests to diagnosis [33-36].
Table 4 Models of diagnosis:a overall costb and numbers of investigations for screening 1,000 adult men or women in
the community for CD
Screen Sex Model
A B C D E F G H
TG2 IgAc F 1,000 1,000 1,000 1,000 – – – –
M 1,000 1,000 1,000 1,000 – – – –
Composite TG2/DGP IgA/IgGc F – – – – – 1,000 1,000 1,000
M – – – – – 1,000 1,000 1,000
HLA-DQd F – – – – 1,000 – – –
M – – – – 1,000 – – –
Confirmatory test if initial test is ‘positive’
TG2 IgAc F – – – – 560 – – –
M – – – – 557 – – –
EMAc F – – 45 3 19 – – –
M – – 69 2 37 – – –
TG2 IgA and DGP-G, DGP-Ae F – – – – – – – 52
M – – – – – – – 79
HLA-DQd F – 45 45 3 – – 52 52
M – 69 69 2 – – 79 79
Biopsy if initial and/or confirmatory tests are positivef
Biopsy F 45 32 32 42 18 52 38 28
M 69 45 45 67 16 79 48 24
Cases diagnosedg F 13 13 13 13 13 19 19 19
M 13 13 13 13 13 12 12 12
Total cost for investigations, A$ F 63,150 57,484 58,605 61,034 149,367 69,100 63,422 57,010
M 83,550 71,406 73,124 82,139 148,041 92,050 75,152 57,924
Cost per case screened, A$ F 63 57 59 61 149 69 63 57
M 84 71 73 82 148 92 75 58
Cost per case diagnosed, A$ F 4,858 4,422 4,508 4,695 11,490 3,637 3,338 3,001
M 6,427 5,493 5,625 6,318 11,388 7,671 6,263 4,827
Abbreviations: CD, celiac disease; DGP, Deamidated gliadin-derived peptide; EMA, endomysial antibody; HLA, human leukocyte antigen; TG, transglutaminase.
aData are n, unless otherwise stated.
bCosts are based on 100% reimbursement of Australian Medicare Benefits Schedule fee for items c71163: A$24.90, d71151: A$119.65, e71164: A$40.15, and fA$850
estimated costs of gastroscopy, histology, sedation, and hospital/clinic facility fee.
gCases diagnosed were assumed to be the excess of HLA-DQ2.5/8/2.2 subjects in those screened by TG2 IgA (models A to E), or composite antigen ELISA (model
F to H), as detailed in Table 1.
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defining the community prevalence of CD [1]. From
1,000 randomly selected Swedish adults who underwent
diagnostic gastroscopy, 33 were TG2 IgA-positive, and
16 of these were also EMA-positive. These 16 subjects
who were seropositive for both TG2 IgA and EMA were
considered to have CD, but only 12 of the 16 EMA sub-
jects showed both villous atrophy and increased density
of IELs; of the other 4 patients, 3 showed only increased
IELs and the fourth had normal histology. In addition,
two of the TG2 IgA+ EMA− subjects also showed partial
villous atrophy and raised IEL numbers. Walker et al.
speculated that if increased TG2 IgA with normal intes-
tinal histology or raised IEL numbers without increasedTG2-IgA reflected gluten-mediated pathology, then the
community prevalence of CD might be considerably
greater than their estimate of almost 2% [1].
Consistent with a previous study from Australia and
several from Europe and North America [14,20,37,38],
over 98% of locally recruited volunteers with ‘biopsy-
confirmed’ CD possessed HLA-DQ2.5, DQ8, or DQ2.2.
In addition, we found that absence of HLA-DQ2.5,
DQ8, or DQ2.2 in ‘biopsy-confirmed’ cases predicted in-
correct diagnosis. Building upon this observation, we de-
veloped a novel method to estimate the prevalence of
CD in two large age-stratified, randomly selected com-
munity cohorts, based on the relative enrichment for
HLA-DQ alleles conveying genetic susceptibility to CD
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serology tests. If, as some previous studies have done, we
had assumed that all TG2 IgA-seropositive individuals
with HLA-DQ2.5, DQ8, or DQ2.2 did have CD, then we
would have estimated community prevalence to be 3.1%
in women and 4.8% in men. The novel serogenetic ap-
proach we developed potentially overcomes not only the
need for biopsy but also performance variation between
different TG2 IgA ELISAs when estimating the preva-
lence of CD in the community. In this study, we esti-
mated that 1.3% of men and women in the community
had unrecognized CD using TG2 IgA serology. However,
our finding that two TG2 IgA-seronegative women who
were positive in the composite TG2/DGP IgA/IgG
screen were subsequently confirmed to have CD on
small bowel histology added support to the higher
prevalence figure of 1.9% for women, estimated using
the composite TG2/DGP IgA/IgG screen.
Clinical follow-up confirmed 10 new cases of
unrecognized CD in addition to 7 cases diagnosed through
standard medical care before or during the current pro-
spective study. As anticipated, the biopsy-confirmed
prevalence of CD of 0.7% in women and 0.6% in men was
substantially less than by the serogenetic method. How-
ever, for a variety of reasons, seven additional cases with
persistent serological abnormalities did not undergo gas-
troscopy, and more than half of the cases who were posi-
tive in the composite TG2/DGP IgA/IgG screen were not
available for follow-up or had no additional investigation.
Medical review of seropositive subjects by their primary
care physicians also highlighted the persisting misconcep-
tion that CD only presents with classical symptoms. Al-
though use of a gluten-free diet has become much more
popular since the enrolment sera were collected, none of
the subjects with raised CD-specific serology reported
having adopted gluten-free diet, apart from those actually
diagnosed with CD. However, it is possible that deliberate
or inadvertent reduction of dietary gluten by some
formerly seropositive subjects could have resulted in
normalization of serological abnormalities.
Testing for CD is increasing. Claims for serological
testing for CD reimbursed by Medicare Australia in the
State of Victoria rose from 9.3 per 1,000 population in
2004 to 14.4 per 1,000 population in 2009; the total
number of claims during this 6-year period was 72.4 per
1,000 population. Females and males aged over 15 years
accounted for 63% and 23%, respectively, of all Medicare
claims for coeliac disease serology tests in 2010. Between
2004 and 2009, 4 of the estimated 12 to 26 unrecognized
cases of CD in our female cohort and 2 of the estimated
12 to 16 unrecognized cases in our male cohort were di-
agnosed through standard medical care. Over time, as
testing increases, the total number of undiagnosed adult
cases of CD would be expected to fall steadily,particularly in women. The combined effects of in-
creased testing and increased diagnoses would eventually
reduce the pre-test probability of CD when testing pa-
tients in primary care. TG2 IgA serology is widely
recommended as the initial investigation when CD is
considered, but based on serogenetic data from the
current study, fewer than one in three women and one
in five men with abnormal TG2 IgA in the community
would be expected to have unrecognized CD. Hopper et
al. also reported similarly high rates of false positives
using a different TG2 IgA assay in a group of 2,000 pa-
tients referred for gastroscopy [8]. If gastroscopy with
intestinal biopsy continues to be recommended as the
next step after positive TG2 IgA serology, many un-
necessary gastroscopies will be performed, at consider-
able expense and inconvenience for patients.
To address this problem, we modeled the practical
and financial effects of including confirmatory serology
and genetic testing after initial testing and before ‘defini-
tive’ small bowel histology. Inclusion of genetic testing
after either TG2 IgA or composite TG2/DGP IgA/IgG
serology reduced gastroscopies and overall costs
incurred according to the current Medicare Australia re-
imbursement schedule. Inclusion of confirmatory ser-
ology after initial testing with composite TG2/DGP IgA/
IgG serology had a similar effect by reducing gastrosco-
pies without appreciably affecting detection rates, and
also lowering overall costs according to pricings in
Australia. The applicability and financial effect of the
diagnostic algorithms are likely to vary between coun-
tries and healthcare systems, depending on local labora-
tory facilities and costing. However, the community rates
of ‘positive’ and ‘negative’ serologies and the genetic sus-
ceptibility data presented in the current study can be
combined with relevant local costs for laboratory assays
and procedures to predict which diagnostic pathway
might be the most relevant and cost-effective in a par-
ticular setting.
Although it would be premature to formally propose a
‘single’ diagnostic flow chart, the present study highlights
the effects of separating initial laboratory testing by ser-
ology from a second set of laboratory tests in order to
further increase the likelihood of CD before proceeding
to endoscopic biopsy and histology, which is definitive
but also the most expensive and intrusive investigation
used in diagnostic investigations for CD. Shifting costs
from gastroscopy to laboratory testing promises to re-
duce overall costs and may be more acceptable to pa-
tients, particularly if gastroscopy is difficult to access or
even undesirable.
Conclusions
The exceptional performance characteristics of CD-
specific serology and HLA-DQ genetic testing have
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nose CD. In the current study, a novel serogenetic
methodology was developed to formally estimate the
community prevalence of CD by optimizing combined
serological and genetic testing. In contrast to conflicting
reports that the prevalence of CD is overestimated or
underestimated due to discordance in intestinal hist-
ology and TG2-IgA serology, screening using TG2-IgA,
EMA, and HLA-DQ genetic testing indicates that the
prevalence of CD in adults is at least 1.1% in men and
1.0% in women, but when TG2 and DGP serology are
combined as initial screening tools, sensitivity is im-
proved, and the estimated prevalence of CD is 1.2% or
1:86 in men and 1.9% or 1:52 in women. Serogenetic
screening without the requirement for follow-up small
bowel biopsies provides a flexible, cost-effective method-
ology that could be widely applied to obtain accurate es-
timates of the prevalence of CD in large cohort studies.
In the current study, the serogenetic screening also
highlighted that false-positive TG2-IgA serology is com-
mon in adults at average risk of CD. Using serology and
genetic tests after initial serology screening is both cost-
effective and could avoid many unnecessary gastrosco-
pies prompted by abnormal ‘CD-specific’ serology.
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